Posted by Michael Wonder on 05 Sep 2024
Breakthrough therapy designation for Sanbexin sublingual tablets granted by the US FDA
5 September 2024 - On 2 September 2024, Simcere Pharmaceuticals announced that Sanbexin sublingual tablets (edaravone and dexborneol sublingual tablets), an innovative drug for stroke, has been granted the breakthrough therapy designation by the US FDA for the treatment of acute ischaemic stroke.
Sanbexin sublingual tablets is the first innovative drug in the world to be designated with the breakthrough therapy by the FDA for the treatment of stroke.
